UY39007A - Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas - Google Patents

Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas

Info

Publication number
UY39007A
UY39007A UY0001039007A UY39007A UY39007A UY 39007 A UY39007 A UY 39007A UY 0001039007 A UY0001039007 A UY 0001039007A UY 39007 A UY39007 A UY 39007A UY 39007 A UY39007 A UY 39007A
Authority
UY
Uruguay
Prior art keywords
dextrometadone
diseases
neuropsychiatric disorders
disease modifying
modifying treatment
Prior art date
Application number
UY0001039007A
Other languages
English (en)
Inventor
L Manfredi Paolo
E Inturrisi Charles
De Martin Sara
Jacopo Sgrignani
Andrea Mattarei
Andrea Cavalli
Original Assignee
Univ Of Padova
Inst Res Biomedicine
L Manfredi Paolo
E Inturrisi Charles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Padova, Inst Res Biomedicine, L Manfredi Paolo, E Inturrisi Charles filed Critical Univ Of Padova
Publication of UY39007A publication Critical patent/UY39007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)

Abstract

Métodos y composiciones para modificar el curso y severidad de trastornos neuropsiquiátricos. El método incluye administrar una composición a un sujeto que sufre de un trastorno neuropsiquiátrico, caracterizado porque la composición incluye una sustancia seleccionada de dextrometadona, metabolitos de dextrometadona, d-metadol, d-alfa-acetilmetadol, d-alfa-normetadol, l-alfa-normetadol, así como las sales de los mismos aceptables desde el punto de vista farmacéutico.
UY0001039007A 2020-01-03 2021-01-05 Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas UY39007A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062956839P 2020-01-03 2020-01-03
US202062963874P 2020-01-21 2020-01-21
US202062993188P 2020-03-23 2020-03-23
US202063010391P 2020-04-15 2020-04-15
US202063031785P 2020-05-29 2020-05-29

Publications (1)

Publication Number Publication Date
UY39007A true UY39007A (es) 2021-07-30

Family

ID=76687448

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039007A UY39007A (es) 2020-01-03 2021-01-05 Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas

Country Status (12)

Country Link
US (1) US20230017786A1 (es)
EP (1) EP4085044A4 (es)
JP (1) JP2023509484A (es)
KR (1) KR20220164470A (es)
CN (1) CN115397804A (es)
AU (1) AU2020419181A1 (es)
BR (1) BR112022013160A2 (es)
CA (1) CA3166254A1 (es)
MX (1) MX2022007768A (es)
TW (1) TW202140415A (es)
UY (1) UY39007A (es)
WO (1) WO2021138443A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US9468611B2 (en) * 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system
BR112019024802A2 (pt) * 2017-05-25 2020-07-21 Glytech Llc. terapia combinada para transtornos neuropsiquiátricos responsivos ao antagonista de nmdar
CN113646044A (zh) * 2019-01-30 2021-11-12 帕多瓦大学 用于预防和治疗疾病和病症的结构修饰的阿片类药物

Also Published As

Publication number Publication date
BR112022013160A2 (pt) 2022-11-08
EP4085044A4 (en) 2024-06-12
TW202140415A (zh) 2021-11-01
KR20220164470A (ko) 2022-12-13
CA3166254A1 (en) 2021-07-08
JP2023509484A (ja) 2023-03-08
AU2020419181A1 (en) 2022-07-21
CN115397804A (zh) 2022-11-25
US20230017786A1 (en) 2023-01-19
WO2021138443A1 (en) 2021-07-08
MX2022007768A (es) 2022-09-27
EP4085044A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
CO2019005922A2 (es) Variantes de il-2 para el tratamiento de enfermedades autoinmunes
ECSP21027049A (es) Inhibidores de la proteína tirosina fosfatasa
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CL2017002526A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015)
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO2020016582A2 (es) Sales de sepiapterina farmacéuticamente aceptables
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
UY39188A (es) Imidazopiridazinas como moduladores de il-17
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2020012359A2 (es) Moduladores calpaína y usos terapéuticos de los mismos
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
CO2019010120A2 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
BR112023019211A2 (pt) Inibidores de inflamassoma nlrp3
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.